DEPARTMENT OF HEALTH & HUMAN SERVICES

Public Health Service

Food and Drug Administration
Rockville MD 20857

Re: GLYSET™
Docket No. 97E-0077

#244

JUL - 8 1997

The Honorable Bruce Lehman
Assistant Secretary of Commerce and
Commissioner of Patents and Trademarks
Box Pat. Ext.
Assistant Commissioner for Patents
Washington, D.C. 20231

Dear Commissioner Lehman:

This is in regard to the application for patent term extension for U.S. Patent No. 4,639,436, filed by Bayer Aktiengesellschaft, under 35 U.S.C. § 156 et seq. We have reviewed the dates contained in the application and have determined the regulatory review period for GLYSET™, the human drug product claimed by the patent.

The total length of the regulatory review period for GLYSET™ is 4,900 days. Of this time, 4,544 days occurred during the testing phase and 356 days occurred during the approval phase. These periods of time were derived from the following dates:

1. The date an exemption under subsection 505(i) of the Federal Food, Drug, and Cosmetic Act involving this drug product became effective: July 22, 1983.

   FDA has verified the applicant's claim that the date the Investigational New Drug application became effective was on July 22, 1983.

2. The date the application was initially submitted with respect to the human drug product under subsection 505(b) of the Federal Food, Drug, and Cosmetic Act: December 29, 1995.

   FDA has verified the applicant's claim that the New Drug Application (NDA) for GLYSET (NDA 20-682) was initially submitted on December 29, 1995.

3. The date the application was approved: December 18, 1996.

   FDA has verified the applicant's claim that NDA 20-682 was approved on December 18, 1996.

This determination of the regulatory review period by FDA does not take into account the effective date of the patent, nor does it exclude one-half of the testing phase as required by 35 U.S.C. § 156(c)(2).

Please let me know if we can be of further assistance.

Sincerely yours,

for Stuart L. Nightingale, M.D.
Associate Commissioner
for Health Affairs

cc: Jeffrey M. Greenman, Esq.
Bayer Corporation
400 Morgan Lane
West Haven, CT 06516